Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: A multicentre randomised trial

Lancet

Volumn 361, Issue 9356, 2003, Pages 457-464

  Maughan, T S ^a   James, R D ^b   Kerr, D J ^c   Ledermann, J A ^d   Seymour, M T ^e   Topham, C ^f   McArdle, C ^g   Cain, D ^h   Stephens, R J ^h  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b MAIDSTONE HOSPITAL   (United Kingdom)

^c RADCLIFFE INFIRMARY   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^f ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^g GLASGOW ROYAL INFIRMARY   (United Kingdom)

^h MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINATE CALCIUM; RALTITREXED;

ACUTE DIARRHEA; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOSENSITIVITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HUMAN; INTERMETHOD COMPARISON; LETHARGY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT PLANNING; UNITED KINGDOM; VOMITING;

EID: 0037425721     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12461-0     Document Type: Article

References (30)

1. Seymour M.T., Stenning S.P., Cassidy J. Attitudes and practice in the management of metastatic colorectal cancer in Britain. Clin Oncol. 9:1997;248-251.
2. Ito K., Kato T., Koike A., et al. Optimum duration of oral adjuvant chemotherapy of HCFU for colorectal cancer: review of 5-year follow-up. Anticancer Res. 20:2000;4681-4686.
3. O'Connell M.J., Laurie J.A., Shepherd L., et al. A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: a collaborative trial of the North Central Cancer Treatment Group and the National Cancer Institute of Canada Clinical Trials Group. Proc Am Soc Clin Oncol. 15:1996;209.
4. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet. 339:1992;71-85.
5. Gregory R.K., Powles T.J., Chang J.C., Ashley S. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer. 33:1997;2194-2197.
6. Beith J.M., Clarke S.J., Woods R.L., Bell D.R., Levi J.A. Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. Eur J Cancer. 32A:1996;438-443.
7. Buccheri G.F., Ferrigno D., Curcio A., et al. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Cancer. 63:1989;428-432.
8. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12000 randomised children. Lancet. 347:1996;1783-1788.
9. Elonen E., Almqvist A., Hanninen A., et al. Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group. Leukemia. 12:1998;1041-1048.
10. Einhorn L.H., Williams S.D., Loehrer P.J., et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol. 7:1989;387-391.
11. Hakes T.B., Chalas E., Hoskins W.J., et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol. 45:1992;284-289.
12. Bertelsen K., Jakobsen A., Stroyer I., et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol. 49:1993;30-36.
13. Pavlovsky S., Schvartzman E., Lastiri F., et al. Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease. J Clin Oncol. 15:1997;2652-2658.
14. Coates A., Gebski V., Bishop J.F., et al. Improving the quality of life during chemotherapy for advanced breast cancer. N Engl J Med. 317:1987;1490-1495.
15. Ejlertsen B., Pfeiffer P., Pedersen D., et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer. 29A:1993;527-531.
16. Harris A.L., Cantwell B.M.J., Carmichael J., et al. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet. 335:1990;186-190.
17. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol. 18:2000;3115-3124.
18. Smalley R.V., Murphy S., Huguley C.M. Jnr, Bartolucci A.A. Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Cancer Res. 36:1976;3911-3916.
19. Muss H.B., Case L.D., Richards F. II, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med. 325:1991;1342-1348.
20. Fisher R.I., DeVita V.T., Hubbard S.P., et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med. 90:1979;761-763.
21. Paccagnella A., Cartei G., Fosser V., et al. Treatment of multiple myeloma with M-2 protocol and without maintenance therapy. Eur J Cancer. 19:1983;1345-1351.
22. Maughan T.S., James R.D., Kerr D.J., et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet. 359:2002;1555-1563.
23. De Gramont A., Bosset J.F., Milan C., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup trial. J Clin Oncol. 15:1997;808-815.
24. Lokich J.J., Ahlgren J.D., Cantrell J., et al. A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program study. Cancer. 67:1991;14-19.
25. Cunningham D., Zalcberg J.R., Rath U., et al. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluourouracil plus leucovorin in advanced colorectal cancer. Ann Oncol. 7:1996;961-965.
26. Zigmond A.S., Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychol Scand. 67:1983;361-370.
27. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 85:1993;365-376.
28. Seymour M.T., Slevin M.L., Kerr D.J., et al. Randomized trial assessing the addition of interferon alpha-2a to fluourouracil and leucovorin in advanced colorectal cancer. J Clin Oncol. 14:1996;2280-2288.
29. Spiro S.G., Souhami R.L. Duration of chemotherapy in small cell lung cancer. Thorax. 45:1990;1-2.
30. Giacchetti S., Itzhaki M., Gruia G., et al. Long term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 10:1999;663-669.